NCOG-40. UTILITY OF THE SEIZURE CONTROL COMPOSITE INDEX (RANO-SCCI) IN EVALUATING SEIZURES IN CNS TUMOR PATIENTS

Abstract BACKGROUND Seizures are a common symptom in patients with CNS tumors. The RANO-Seizure Control Composite Index (RANO-SCCI) was developed to monitor seizures over time by and clinicians. We describe the use of RANO-SCCI as part NCI NOB-Natural History Study. METHODS Patients completed prior their clinic appointment results shared clinicians who then same appointment. Seizure reports were tallied respondent type further tumor grade. Concordance between patient clinician report also investigated. RESULTS One hundred fifty-seven underwent 250 clinical evaluations. Participants primarily white (82%) males (57%) median age 47 years (range: 19 – 78). Most had high grade (60%) primary brain (86%) tumors, surveillance (76%), no recurrence KPS ≥ 90 (76%). Half 62% reported ever having seizure. 12% discordance all where did not seizure, but did. There good agreement on seizure reporting since last visit (74% patients, 78% clinicians), anti-seizure medication (51% 57% clinicians). more frequently high-grade tumors (WHO Grade 3 or 4) (60% 76% clinicians) versus low-grade 1 2) 59% among oligodendrogliomas (71% 85% non-oligodendroglioma (54% 68% CONCLUSIONS used for self-report activity. A higher frequency oligodendroglioma Disparities responses may reveal limitation patient’s ability recognize assess symptoms. Further work will investigate congruence associations demographic characteristics.